NASDAQ:KALA 4 December 2025 - 5 December 2025

KALA BIO, Inc. has turned into one of the most volatile biotech penny stocks on the market in late 2025. After a failed eye‑disease trial, a loan default and a near‑miss with foreclosure, the company is now trying to recapitalize itself with fresh equity and new leadership.

As of December 4, 2025, KALA BIO, Inc. has turned into one of the wildest tickers on the Nasdaq. The stock is trading around $1.40 in heavy volume, up roughly 50% on the day after a cascade of news: a $10 million registered direct offering, a loan settlement that turns lender Oxford Finance into a 16.5% shareholder, and a $6 million rescue-style preferred investment from new CEO David Lazar. All this arrives barely two months after KALA’s lead drug failed a key trial, its lender swept most of its cash, and management warned of “substantial doubt” about its ability to survive as a going concern. GlobeNewswire+3Stock Titan+3Stock Titan+3